The economic impact of irritable bowel syndrome
dc.contributor.author | Inadomi, John M. | en_US |
dc.contributor.author | Fennerty, M. B. | en_US |
dc.contributor.author | Bjorkman, D. | en_US |
dc.date.accessioned | 2010-06-01T21:12:16Z | |
dc.date.available | 2010-06-01T21:12:16Z | |
dc.date.issued | 2003-10 | en_US |
dc.identifier.citation | Inadomi, J. M.; Fennerty, M. B.; Bjorkman, D. (2003). "The economic impact of irritable bowel syndrome." Alimentary Pharmacology & Therapeutics 18(7): 671-682. <http://hdl.handle.net/2027.42/74284> | en_US |
dc.identifier.issn | 0269-2813 | en_US |
dc.identifier.issn | 1365-2036 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74284 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14510740&dopt=citation | en_US |
dc.description.abstract | Background : Although little mortality is associated with irritable bowel syndrome, curative therapy does not exist and thus the economic impact of this disorder may be considerable. Methods : A systematic review of the literature was performed. Studies were included if their focus was irritable bowel syndrome, and direct and/or productivity (indirect) costs were reported. Two investigators abstracted the data independently. Results : One hundred and seventy-four studies were retrieved by the search; 11 fulfilled all criteria for entry into the review. The mean direct costs of irritable bowel syndrome management were reported to be UK£90, Canadian$259 and US$619 per patient annually, with total annual direct costs related to irritable bowel syndrome of £45.6 million (UK) and $1.35 billion (USA). Direct resource consumption of all health care for irritable bowel syndrome patients ranged from US$742 to US$3166. Productivity costs ranged from US$335 to US$748, with total annual costs of $205 million estimated in the USA. Annual expenditure for all health care, in addition to expenditure limited to gastrointestinal disorders, was significantly higher in irritable bowel syndrome patients than in control populations. Conclusions : Despite the lack of significant mortality, irritable bowel syndrome is associated with high direct and productivity costs. Irritable bowel syndrome patients consume more gastrointestinal-related and more total health care resources than non-irritable bowel syndrome controls, and sustain significantly greater productivity losses. | en_US |
dc.format.extent | 138249 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Ltd | en_US |
dc.rights | 2003 Blackwell Publishing Ltd | en_US |
dc.title | The economic impact of irritable bowel syndrome | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | * The VA Center for Practice Management and Outcomes Research, and Division of Gastroenterology, Department of Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | † Division of Gastroenterology, Department of Medicine, Oregon Health and Science University, Portland, OR, USA | en_US |
dc.contributor.affiliationother | † Division of Gastroenterology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA | en_US |
dc.identifier.pmid | 14510740 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74284/1/j.1365-2036.2003.t01-1-01736.x.pdf | |
dc.identifier.doi | 10.1046/j.1365-2036.2003.t01-1-01736.x | en_US |
dc.identifier.source | Alimentary Pharmacology & Therapeutics | en_US |
dc.identifier.citedreference | Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 653 – 4. | en_US |
dc.identifier.citedreference | Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999; 45 ( Suppl. 2 ): II1 – 5. | en_US |
dc.identifier.citedreference | Lynn RB, Friedman LS. Irritable bowel syndrome. N Engl J Med 1993; 329: 1940 – 5. | en_US |
dc.identifier.citedreference | Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 2120 – 37. | en_US |
dc.identifier.citedreference | Talley NJ. Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Best Pract Res Clin Gastroenterol 1999; 13: 371 – 84. | en_US |
dc.identifier.citedreference | Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990; 99: 409 – 15. | en_US |
dc.identifier.citedreference | Everhart JE, Go VL, Johannes RS, Fitzsimmons SC, Roth HP, White LR. A longitudinal survey of self-reported bowel habits in the United States. Dig Dis Sci 1989; 34: 1153 – 62. | en_US |
dc.identifier.citedreference | Sandler RS, Drossman DA, Nathan HP, McKee DC. Symptom complaints and health care seeking behavior in subjects with bowel dysfunction. Gastroenterology 1984; 87: 314 – 8. | en_US |
dc.identifier.citedreference | Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569 – 80. | en_US |
dc.identifier.citedreference | Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500 – 11. | en_US |
dc.identifier.citedreference | El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002; 16: 1171 – 85. | en_US |
dc.identifier.citedreference | Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med 2001; 344: 1846 – 50. | en_US |
dc.identifier.citedreference | Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics 2000; 17 ( 4 ): 331 – 8. | en_US |
dc.identifier.citedreference | Jacobs P. The Economics of Health and Medical Care. Rockville, MD: Aspen Publishers, 1991. | en_US |
dc.identifier.citedreference | Schramm C. Health Care and its Costs. New York: Norton, 1987. | en_US |
dc.identifier.citedreference | Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100: 998 – 1005. | en_US |
dc.identifier.citedreference | Talley NJ, Zinsmeister AR, Melton LJ 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995; 142: 76 – 83. | en_US |
dc.identifier.citedreference | Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001; 120 ( 3 ): 652 – 68. | en_US |
dc.identifier.citedreference | Finkler SA. The distinction between cost and charges. Ann Intern Med 1982; 96: 102 – 9. | en_US |
dc.identifier.citedreference | Lundberg GD. Costs, charges, conscience, and control (lost). J Am Med Assoc 1983; 250: 2509. | en_US |
dc.identifier.citedreference | Price KF. Pricing Medicare's diagnosis-related groups: charges versus estimated costs. Health Care Financ Rev 1989; 11: 79 – 90. | en_US |
dc.identifier.citedreference | Oxman AD, Cook DJ, Guyatt GH. Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. J Am Med Assoc 1994; 272: 1367 – 71. | en_US |
dc.identifier.citedreference | Guyatt GH, Sinclair J, Cook DJ, Glasziou P. Users' guides to the medical literature. XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group. J Am Med Assoc 1999; 281: 1836 – 43. | en_US |
dc.identifier.citedreference | Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109 ( 6 ): 1736 – 41. | en_US |
dc.identifier.citedreference | Coremans G, Dapoigny M, Muller-Lissner S, et al. Diagnostic procedures in irritable bowel syndrome. Digestion 1995; 56 ( 1 ): 76 – 84. | en_US |
dc.identifier.citedreference | Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11 ( 6 ): 1019 – 30. | en_US |
dc.identifier.citedreference | Bentkover JD, Field C, Greene EM, Plourde V, Casciano JP. The economic burden of irritable bowel syndrome in Canada. Can J Gastroenterol 1999; 13 ( Suppl. A ): 89A – 96A. | en_US |
dc.identifier.citedreference | Levy RL, Whitehead WE, Von Korff MR, Feld AD. Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol 2000; 95 ( 2 ): 451 – 6. | en_US |
dc.identifier.citedreference | Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001; 96 ( 11 ): 3122 – 9. | en_US |
dc.identifier.citedreference | Creed F, Ratcliffe J, Fernandez L, et al. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001; 134 ( 9 ): 860 – 8. | en_US |
dc.identifier.citedreference | Suleiman S, Sonnenberg A. Cost-effectiveness of endoscopy in irritable bowel syndrome. Arch Intern Med 2001; 161 ( 3 ): 369 – 75. | en_US |
dc.identifier.citedreference | Patel R, Petitta A, Fogel R, Peterson E, Zarowitz B. The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol 2002; 35: 14 – 20. | en_US |
dc.identifier.citedreference | Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002; 20: 455 – 62. | en_US |
dc.identifier.citedreference | Houghton LA, Heyman DJ, Whorwell PJ. Symptomatology, quality of life and economic features of irritable bowel syndrome—the effect of hypnotherapy. Aliment Pharmacol Ther 1996; 10 ( 1 ): 91 – 5. | en_US |
dc.identifier.citedreference | Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.